Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on innovative therapies for neurodegenerative and metabolic disorders, was featured on the latest episode of The BioMedWire Podcast. Co-founder and executive co-chair Anthony Durkacz discussed the company’s lead drug candidate, Lucid-MS, and its commercial alcohol metabolism product, unbuzzd(TM), highlighting the strategic growth opportunities for both assets.
Lucid-MS is being developed to address mobility loss associated with multiple sclerosis (MS) by targeting nerve damage. Durkacz emphasized that current treatments do not adequately address this unmet need. The drug candidate has shown promise in preclinical models by preventing and reversing myelin degradation, the underlying mechanism of MS. Quantum BioPharma is preparing for a Phase 2 clinical trial, which will be the first to evaluate Lucid-MS in MS patients, following Phase 1 testing in healthy volunteers.
In addition to its pipeline, the company has a commercial product, unbuzzd(TM), designed to accelerate blood alcohol metabolism. Available in the U.S. market, unbuzzd(TM) is sold by Unbuzzd Wellness Inc., a company spun out from Quantum. Quantum retains a 19.84% ownership stake in Unbuzzd as of March 31, 2026, and receives royalty payments of 7% of sales from unbuzzd(TM) until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum also retains full rights to develop similar products for pharmaceutical and medical uses.
The podcast appearance underscores Quantum BioPharma’s dual strategy: advancing a high-potential drug candidate in a large market while generating near-term revenue from a consumer product. Multiple sclerosis affects approximately 2.8 million people worldwide, and the global MS treatment market is expected to grow significantly. If Lucid-MS successfully demonstrates efficacy in Phase 2, it could address a critical gap in MS care.
Meanwhile, unbuzzd(TM) provides a steady income stream through royalties and equity, supporting the company’s research and development efforts. The product’s commercial availability also validates Quantum’s ability to bring innovations to market.
Investors can stay updated on Quantum BioPharma’s progress through the company’s newsroom at https://ibn.fm/QNTM. The company’s focus on both therapeutic and consumer health products positions it uniquely in the biotech landscape, balancing long-term drug development with immediate commercial revenue.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Quantum BioPharma Advances Multiple Sclerosis Drug Candidate and Alcohol Metabolism Product.